<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637243</url>
  </required_header>
  <id_info>
    <org_study_id>035.HPB.2018.R</org_study_id>
    <nct_id>NCT04637243</nct_id>
  </id_info>
  <brief_title>Outcomes From Treatment Liver and Bile Duct Diseases</brief_title>
  <official_title>Evaluation of Outcomes From Treatment of Benign or Malignant Liver and Bile Duct Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is reported in the literature that the treatment of any liver and bile duct disease&#xD;
      process, whether benign or malignant, continues to be a huge challenge. For example, patients&#xD;
      with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical&#xD;
      options that are improving in terms of outcome measurements but with much more room for&#xD;
      improvement. Our goal is to continue to review our treatment outcomes to further improve&#xD;
      overall survival, overall symptom control, mortality and morbidity.&#xD;
&#xD;
      The main aim of this study is to evaluate and compare the outcomes from our multiple&#xD;
      treatments of benign or malignant liver and bile duct diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a retrospective chart review of patients who have been diagnosed with&#xD;
      benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D.,&#xD;
      Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in&#xD;
      Richardson, T.X. We plan to conduct an analysis of patients meeting the inclusion criteria&#xD;
      form 2005 to present (up to the day before this study receives IRB approval). Charts will&#xD;
      also be reviewed by the PI. Sub-I, Fellows, Office Staff, Clinical Research Coordinator who&#xD;
      are delegated to do so by the PI. Data will be obtained from a national database. Data will&#xD;
      be analyzed primarily by the study conductors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2019</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality from Treatment of Benign or Malignant Liver and Bile Duct Diseases</measure>
    <time_frame>2005 to present</time_frame>
    <description>Mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity from Treatment of Benign or Malignant Liver and Bile Duct Diseases</measure>
    <time_frame>2005 to present</time_frame>
    <description>Morbidity</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Benign or Malignant Liver and Bile Duct Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment of Benign or Malignant Liver and Bile Duct Diseases</intervention_name>
    <description>Available treatment of Benign or Malignant Liver and Bile Duct Diseases</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who have been diagnosed with benign or malignant liver and bile duct disease under&#xD;
        the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D.,&#xD;
        Sc.M at Methodist Health System Hospital in Richardson, T.X.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients diagnosed and treated for liver and bile duct disease benign or malignant&#xD;
             from 2005 to present (up to the day before this study receives IRB approval)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that are not diagnosed with or treated for liver and bile duct disease&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhiresh Jeyarajah, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trinity Surgical Consultants, Methodist Richardson Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crystee Cooper, DHEd</last_name>
    <phone>214-947-1280</phone>
    <email>CrysteeCooper@mhd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitasha Phatak, Ph.D.</last_name>
    <phone>214-947-4459</phone>
    <email>NitashaPhatak@mhd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Methodist Richardson Medical Center</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhiresh Jeyarajah, MD</last_name>
      <phone>972-619-3500</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Duct Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

